NCT06415864
Oral Cladribine B-cell Study
Queen Mary University of London·ClinicalTrials.govCompleted
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Multiple Sclerosis
- Study type
- Observational
Sponsor & location
- Primary sponsor
- Queen Mary University of London
- Location
- London, United Kingdom
Timeline & enrollment
- Phase
- N/A
- Start date
- Jul 01, 2019
- End date
- Jan 31, 2024
- Enrollment
- 10 participants
Primary outcome
To study B cells subsets changes
Summary
To study the impact of cladribine on peripheral and intrathecal B-cell, plasma cells, T cells
 and Tregs
ICD-10 classifications
Multiple sclerosisProgressive systemic sclerosisSystemic sclerosisSystemic sclerosis, unspecifiedDiffuse sclerosis
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06415864
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06415864 through Pure Global AI's free database. This phase not specified trial is sponsored by Queen Mary University of London and is currently Completed. The study focuses on Multiple Sclerosis. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.